Super P Force Pills (Sildenafil Citrate + Dapoxetine) Used to Treat Erectile Dysfunction (ED) & Premature Ejaculation (PE) in Adult Men.

Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. The authors would like to thank Neutec Ar-Ge San & Tic AS Clinical Research Department for their cooperation. This study has been sponsored by Neutec Ar-Ge San & Tic AS (Turkey). The authors declare that they have no conflict of interest. Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

• Future treatments may offer alternatives to Viagra with Dapoxetine.
• Research continues on more effective and safer combination drugs.
• Gene therapy and topical creams are under development for ED.
• Behavioral therapy remains a non-drug option for PE management.
• Stay informed about medical advances through reputable sources.
• Discuss new options with your doctor as they become available.
• Current medication remains reliable for many men worldwide.
• Maintain overall health to enhance any future treatment success.
• Always prioritize safety and professional guidance over convenience.

Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction—DAP-SPEED Study. What Is the Role of Ejaculation Latency in the Diagnosis of Premature Ejaculation and Does the Ejaculation Latency Threshold Matter? Conservative Non-surgical Options for Erectile Dysfunction Current Urology Reports (2023) The role of tyrosine hydroxylase within dapoxetine-assisted therapy against premature ejaculation Molecular Biology Reports (2023) Current and emerging treatment options for premature ejaculation Nature Reviews Urology (2022) Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity Nature Reviews Urology (2021) 058 The Efficacy and Safety of Dapoxetine / Sildenafil Combination Therapy in the Treatment of Men with Premature Ejaculation and Erectile Dysfunction – DAP-SPEED Study - ScienceDirect Please enable JavaScript to use all the features on this page. 058 The Efficacy and Safety of Dapoxetine / Sildenafil Combination Therapy in the Treatment of Men with Premature Ejaculation and Erectile Dysfunction – DAP-SPEED Study Author links open overlay panelM.Tuken1, M.G.Culha2, E.C.Serefoglu3 Premature ejaculation (PE) and erectile dysfunction (ED) are the most prevalent sexual disorders in men.

Dapoxetine Therapy: Serotonin Modulation, Ejaculatory Control, and On-Demand Treatment Strategy

Keywords: dapoxetine, intravaginal ejaculatory latency time, patient-reported outcomes, premature ejaculation Dapoxetine (PriligyTM, Johnson and Johnson, Raritan, NJ) is the first and only product licensed for the treatment of premature ejaculation (PE) in men aged 18–64 years. At present, dapoxetine is licensed in ten countries, including several countries in Europe, and Mexico, South Korea, and New Zealand.1,2 PE is the most common sexual dysfunction in men, with a global prevalence estimated to be between 20% and 40%.3–5 The uncertainty about prevalence figures is due to the intimate nature of the condition and, until recently, the lack of a universal evidence-based definition. It is probable that many men do not admit to having the condition and do not seek medical advice. PE is characterized by ejaculation prior to, or soon after, vaginal penetration with minimal stimulation, with the male having no control over ejaculation. Definitions have been published by the International Society for Sexual Medicine and in the Diagnostic Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), with the key point being the uncontrolled brevity of sexual intercourse.6–8 The negative consequences of PE are significant, and affect both the male and female partner.

Nizagara 100 Mg (Sildenafil Citrate)

As well as obvious sexual dissatisfaction, the condition can cause personal distress, low self-esteem, and interpersonal difficulty.5,9–11 Dapoxetine belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs) which are frequently used to treat depression. Prior to the availability of dapoxetine, psychotherapy (eg, cognitive behavior therapy) was widely used to treat PE. More recently, several SSRIs (other than dapoxetine) have been used off-label to treat PE.12,13 These SSRIs were not developed to treat PE,12 in contrast with dapoxetine which was specifically developed for this purpose and has a different pharmacological profile to the other SSRIs,14–17 with properties making it suitable for on-demand dosing.1 The aims of this article are to review the current evidence for use of dapoxetine in the treatment of PE, including the ability of the drug to not only increase time to ejaculation post-penetration, termed intravaginal ejaculatory latency time (IELT), but also to improve patient self-esteem, satisfaction with sexual intercourse, and perceived control over ejaculation. Literature searches were carried out in August 2011 using PubMed ( the Cochrane Database of Systematic Reviews ( NHS Evidence ( and the National Institute for Health and Clinical Excellence (NICE, These databases were searched using the terms “dapoxetine” or “dapoxetine AND premature ejaculation”. Articles involving dapoxetine for the treatment of PE were identified, with priority given to systematic reviews, meta-analyses and integrated analyses, double-blind, randomized, placebo-controlled clinical trials (RCTs), and nonrandomized observational studies. ED is commonly reported among patients with PE.Although recent guidelines recommend to treat ED first in men with both PE and ED, this recommendation is not based on evidence and there is limited data about the efficacy and safety of dapoxetin / sildenafil combination therapy for these patients. The aim of this study is to evaluate the clinical efficacy and safety of the dapoxetine / sildenafil combination (Dapoxil 30/50 mg film-coated tablet) in the treatment of patients with PE and concomitant ED.

In a single-center, single-arm, open-label clinical study, 74 patients with lifelong / acquired PE and ED were included between October 2016 to September 2017.Patients received on demand dapoxetine / sildenafil (30/50 mg film-coated tablets) 1-3 hours before sexual intercourse for 4 weeks (2 days a week and no more than once a day). All patients were instructed to record their intravaginal ejaculatory latency time (IELT). They were also instructed to complete Premature Ejaculation Diagnostic The study was completed with 53 patients (71.62%).

Side Effects

The global prevalence of PE is estimated to be between 20% and 40%, making it the most common sexual dysfunction in men. PE causes distress and reduced quality of life for patients and has a negative impact on interpersonal relationships. Historically, it has been treated with cognitive therapy, behavioral methods, and off-label use of selective serotonin reuptake inhibitors usually used to treat depression and other psychological disorders. Dapoxetine is a selective serotonin reuptake inhibitor specifically designed to treat PE. This paper reviews the current evidence for use of dapoxetine in the treatment of PE in adult men.

Generic Priligy 30 Mg (Dapoxetine)

There is substantial evidence that dapoxetine 30 mg or 60 viagra medicine mg taken “on-demand” results in a significant increase in intravaginal ejaculatory latency time when compared with placebo. Patient-reported outcomes are clearly improved relative to placebo following dapoxetine therapy, indicating greater control over ejaculation, more satisfaction with intercourse, less ejaculation-related distress, and, importantly, significantly reduced interpersonal difficulty. These data were supported by consistent reports of improvement in Clinical Global Impression of change in PE following treatment with dapoxetine. Further studies are needed to evaluate long-term efficacy and health economics. The unique pharmacology of dapoxetine makes it ideal for on-demand dosing, and the clinical evidence shows dapoxetine to be an efficacious and tolerable treatment for lifelong and acquired PE. Mean age of the patients was 45.32±10.05. Before the treatment, geometric mean IELT of the patients was 22.72±15.16 seconds, mean PEDT score was 16.85±2.42, mean PEP score was 3.36±1.12and IIEF-EF score was 13.17±3.33. At the end of the 4-week treatment period, statistically significant improvements were observed in the mean IELTs, PEP and IIEF-EF scores compared to the patients' pre-treatment values (69.47±103.34;p<0.001, 9.92±2.36;p<0.001, The dapoxetine/ sildenafil combination therapy significantly improves the IELT values and patient reported outcome measures of PE patients who also suffer from ED.

How can I order Sildenafil–Dapoxetine online?

ED is commonly reported among patients with PE.Although recent guidelines recommend to treat ED first in men with both PE and ED, this recommendation is not based on evidence and there is limited data about the efficacy and safety of dapoxetin / sildenafil combination therapy for these patients. The aim of this study is to evaluate the clinical efficacy and safety of the dapoxetine / sildenafil combination (Dapoxil 30/50 mg film-coated tablet) in the treatment of patients with PE and concomitant ED. In a single-center, single-arm, open-label clinical study, 74 patients with lifelong / acquired PE and ED were included between October 2016 to September 2017.Patients received on demand dapoxetine / sildenafil (30/50 mg film-coated tablets) 1-3 hours before sexual intercourse for 4 weeks (2 days a week and no more than once a day). All patients were instructed to record their intravaginal ejaculatory latency time (IELT). They were also instructed to complete Premature Ejaculation Diagnostic The study was completed with 53 patients (71.62%).

Pharmacokinetics and Rapid Clearance Profile

Mean age of the patients was 45.32±10.05. Before the treatment, geometric mean IELT of the patients was 22.72±15.16 seconds, mean PEDT score was 16.85±2.42, mean PEP score was 3.36±1.12and IIEF-EF score was 13.17±3.33. At the end of the 4-week treatment period, statistically significant improvements were observed in the mean IELTs, PEP and IIEF-EF scores compared to the patients' pre-treatment values (69.47±103.34;p<0.001, 9.92±2.36;p<0.001, The dapoxetine/ sildenafil combination therapy significantly improves the IELT values and patient reported outcome measures of PE patients who also suffer from ED. Although several side effects were reported, these were mild and reversible. Premature ejaculation (PE) is a major issue in male sexual health. Although several side effects were reported, these were mild and reversible. Premature ejaculation (PE) is a major issue in male sexual health.

About this article

Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. The authors would like to thank Neutec Ar-Ge San & Tic AS Clinical Research Department for their cooperation. This study has been sponsored by Neutec Ar-Ge San & Tic AS (Turkey). The authors declare that they have no conflict of interest.

Product Image

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction—DAP-SPEED Study. What Is the Role of Ejaculation Latency in the Diagnosis of Premature Ejaculation and Does the Ejaculation Latency Threshold Matter? Conservative Non-surgical Options for Erectile Dysfunction Current Urology Reports (2023) The role of tyrosine hydroxylase within dapoxetine-assisted therapy against premature ejaculation Molecular Biology Reports (2023) Current and emerging treatment options for premature ejaculation Nature Reviews Urology (2022) Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity Nature Reviews Urology (2021) 058 The Efficacy and Safety of Dapoxetine / Sildenafil Combination Therapy in the Treatment of Men with Premature Ejaculation and Erectile Dysfunction – DAP-SPEED Study - ScienceDirect Please enable JavaScript to use all the features on this page. 058 The Efficacy and Safety of Dapoxetine / Sildenafil Combination Therapy in the Treatment of Men with Premature Ejaculation and Erectile Dysfunction – DAP-SPEED Study Author links open overlay panelM.Tuken1, M.G.Culha2, E.C.Serefoglu3 Premature ejaculation (PE) and erectile dysfunction (ED) are the most prevalent sexual disorders in men. The global prevalence of PE is estimated to be between 20% and 40%, making it the most common sexual dysfunction in men. PE causes distress and reduced quality of life for patients and has a negative impact on interpersonal relationships. Historically, it has been treated with cognitive therapy, behavioral methods, and off-label use of selective serotonin reuptake inhibitors usually used to treat depression and other psychological disorders.

• Viagra with Dapoxetine is not recommended for women or children.
• Men with severe kidney or liver issues should avoid this drug.
• Those with retinitis pigmentosa may face increased vision risks.
• Heart patients must get clearance before starting treatment.
• Diabetic men may require lower doses due to health complications.
• High blood pressure patients should monitor cardiovascular response.
• Consult specialist if you have a history of stroke or seizures.
• Prostate surgery patients may have altered drug sensitivity.
• Age over 65 may require reduced dosage for safety reasons.

Dapoxetine is a selective serotonin reuptake inhibitor specifically designed to treat PE. This paper reviews the current evidence for use of dapoxetine in the treatment of PE in adult men. There is substantial evidence that dapoxetine 30 mg or 60 viagra medicine mg taken “on-demand” results in a significant increase in intravaginal ejaculatory latency time when compared with placebo. Patient-reported outcomes are clearly improved relative to placebo following dapoxetine therapy, indicating greater control over ejaculation, more satisfaction with intercourse, less ejaculation-related distress, and, importantly, significantly reduced interpersonal difficulty.

How long does it take to work?

Vidalista Black 80mg (Tadalafil)

These data were supported by consistent reports of improvement in Clinical Global Impression of change in PE following treatment with dapoxetine. Further studies are needed to evaluate long-term efficacy and health economics. The unique pharmacology of dapoxetine makes it ideal for on-demand dosing, and the clinical evidence shows dapoxetine to be an efficacious and tolerable treatment for lifelong and acquired PE. Keywords: dapoxetine, intravaginal ejaculatory latency time, patient-reported outcomes, premature ejaculation Dapoxetine (PriligyTM, Johnson and Johnson, Raritan, NJ) is the first and only product licensed for the treatment of premature ejaculation (PE) in men aged 18–64 years.

At present, dapoxetine is licensed in ten countries, including several countries in Europe, and Mexico, South Korea, and New Zealand.1,2 PE is the most common sexual dysfunction in men, with a global prevalence estimated to be between 20% and 40%.3–5 The uncertainty about prevalence figures is due to the intimate nature of the condition and, until recently, the lack of a universal evidence-based definition. It is probable that many men do not admit to having the condition and do not seek medical advice. PE is characterized by ejaculation prior to, or soon after, vaginal penetration with minimal stimulation, with the male having no control over ejaculation. Definitions have been published by the International Society for Sexual Medicine and in the Diagnostic Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), with the key point being the uncontrolled brevity of sexual intercourse.6–8 The negative consequences of PE are significant, and affect both the male and female partner. As well as obvious sexual dissatisfaction, the condition can cause personal distress, low self-esteem, and interpersonal difficulty.5,9–11 Dapoxetine belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs) which are frequently used to treat depression. Prior to the availability of dapoxetine, psychotherapy (eg, cognitive behavior therapy) was widely used to treat PE. More recently, several SSRIs (other than dapoxetine) have been used off-label to treat PE.12,13 These SSRIs were not developed to treat PE,12 in contrast with dapoxetine which was specifically developed for this purpose and has a different pharmacological profile to the other SSRIs,14–17 with properties making it suitable for on-demand dosing.1 The aims of this article are to review the current evidence for use of dapoxetine in the treatment of PE, including the ability of the drug to not only increase time to ejaculation post-penetration, termed intravaginal ejaculatory latency time (IELT), but also to improve patient self-esteem, satisfaction with sexual intercourse, and perceived control over ejaculation. Literature searches were carried out in August 2011 using PubMed ( the Cochrane Database of Systematic Reviews ( NHS Evidence ( and the National Institute for Health and Clinical Excellence (NICE, These databases were searched using the terms “dapoxetine” or “dapoxetine AND premature ejaculation”. Articles involving dapoxetine for the treatment of PE were identified, with priority given to systematic reviews, meta-analyses and integrated analyses, double-blind, randomized, placebo-controlled clinical trials (RCTs), and nonrandomized observational studies.

• Viagra with Dapoxetine is not addictive but can be habit-forming.
• Psychological dependence may develop if used without medical need.
• Use only as prescribed to avoid tolerance buildup over time.
• Take breaks if recommended by doctor to reset sensitivity.
• Do not share medication with others, even if symptoms similar.
• Dispose of expired or unused drugs properly per local laws.
• Consult pharmacist for safe disposal methods like take-back programs.
• Avoid stockpiling large quantities to prevent misuse or expiration.
• Regular medical check-ups ensure ongoing safety and efficacy.

Only articles published in English were selected for inclusion. The references listed in identified articles were used as a further source of relevant studies. PE is highly prevalent and, due to the nature of the disorder, is likely to be under-reported and undertreated.5,18 Reported prevalence has also been variable due to the previous lack of an evidence-based definition. In the past, physicians generally considered PE to have a psychological element, hence the historical use of psychotherapy to treat the condition. However, in recent years, the biological component has become more widely understood, and pharmacotherapy is the new focus for the treatment of PE. Two types of PE have been widely recognized, ie, lifelong (primary) and acquired (secondary) PE. Lifelong PE is present from the first sexual experience onwards, occurs in almost all attempts at intercourse, and is considered to have a neurobiological etiology. Secondary PE occurs later in life after a period of perceived normal ejaculatory control, and may have a psychological and neurobiological etiology.

• Viagra with Dapoxetine can be taken with food but delays absorption.
• Fatty meals may reduce effectiveness; opt for light snacks instead.
• Grapefruit juice increases side effect risks; avoid entirely.
• Caffeine may amplify dizziness or jitteriness in some users.
• Stay hydrated but avoid excessive fluid intake before sex.
• Alcohol can impair judgment and increase side effect severity.
• Combining with other stimulants is not advised for safety.
• Follow a consistent routine to achieve optimal drug performance.
• Keep a log of meals and drug timing to track effects.

This type of PE may be triggered by stress or linked to adverse events associated with medications.19,20 Waldinger et al suggested that, in addition to these well known types of PE, there are two other subtypes, ie, natural variable PE and premature-like ejaculatory dysfunction.21 Natural variable PE refers to those men reporting occasional early ejaculation in the course of normal events, whilst with the latter, men experience or complain of PE while having normal or prolonged IELT.22,23 Despite the above classifications, features common to all PE are an inability to control ejaculation, ejaculation prior to/soon after vaginal penetration, embarrassment, low self-esteem, personal distress, and often interpersonal difficulty and relationship problems as a result of the lack of sexual satisfaction for both the man and his partner.6,7 The first evidence-based definition of lifelong PE has recently been published by the International Society for Sexual Medicine, and includes the criterion of “ejaculation which always or nearly always occurs prior to or within about 1 minute of vaginal penetration”, ie, an IELT of 1 minute or less.

A balanced verdict from a pharmacy perspective

Only articles published in English were selected for inclusion. The references listed in identified articles were used as a further source of relevant studies. PE is highly prevalent and, due to the nature of the disorder, is likely to be under-reported and undertreated.5,18 Reported prevalence has also been variable due to the previous lack of an evidence-based definition. In the past, physicians generally considered PE to have a psychological element, hence the historical use of psychotherapy to treat the condition. However, in recent years, the biological component has become more widely understood, and pharmacotherapy is the new focus for the treatment of PE.

Conflict of interest

Two types of PE have been widely recognized, ie, lifelong (primary) and acquired (secondary) PE. Lifelong PE is present from the first sexual experience onwards, occurs in almost all attempts at intercourse, and is considered to have a neurobiological etiology. Secondary PE occurs later in life after a period of perceived normal ejaculatory control, and may have a psychological and neurobiological etiology. This type of PE may be triggered by stress or linked to adverse events associated with medications.19,20 Waldinger et al suggested that, in addition to these well known types of PE, there are two other subtypes, ie, natural variable PE and premature-like ejaculatory dysfunction.21 Natural variable PE refers to those men reporting occasional early ejaculation in the course of normal events, whilst with the latter, men experience or complain of PE while having normal or prolonged IELT.22,23 Despite the above classifications, features common to all PE are an inability to control ejaculation, ejaculation prior to/soon after vaginal penetration, embarrassment, low self-esteem, personal distress, and often interpersonal difficulty and relationship problems as a result of the lack of sexual satisfaction for both the man and his partner.6,7 The first evidence-based definition of lifelong PE has recently been published by the International Society for Sexual Medicine, and includes the criterion of “ejaculation which always or nearly always occurs prior to or within about 1 minute of vaginal penetration”, ie, an IELT of 1 minute or less.